Here's what grant funding news stories trended this year on InnovationMap. Photo via Getty Images

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. Money means a lot to startups and other innovative entities, and while startups are usually scouting venture capital investors, grants and donations are key too. These are the most-read news articles about grants and gifts — be sure to click through to read the full story.

Rice researchers secure $35M federal grant to advance medical device technology

Rice’s Biotech Launch Pad will lead the effort to commercialize the device. Photo courtesy Rice University

Rice University has secured part of a nearly $35 million federal grant aimed at commercializing a bioelectric implant for treatment of type 2 diabetes and obesity.

The federal Advanced Research Projects Agency for Health awarded the $34.9 million grant to Rice and several other universities.

Rice’s Biotech Launch Pad will lead the effort to commercialize the self-contained, implantable Rx On-site Generation Using Electronics (ROGUE) device. ROGUE houses cells that are engineered to produce type 2 diabetes and obesity therapies in response to patients’ needs. Continue reading.

Houston health care institutions receive $22M to attract top recruits

The grants, which are between $2 million to $6 million each, are earmarked for recruitment of prominent researchers. Photo via Getty Images

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14.

Milner, an expert in photomedicine for surgery and diagnostics, is a professor of surgery and biomedical engineering at the Beckman Laser Institute & Medical Clinic at the University of California, Irvine and the university’s Chao Family Comprehensive Cancer Center. Continue reading.

Texas organization grants $68.5M to Houston institutions for recruitment, research

Several Houston organizations have received millions from the Cancer Prevention and Research Institute of Texas. Photo via tmc.edu

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.” Continue reading.

Houston health care institution secures $100M for expansion, shares renderings

Baylor College of Medicine's Lillie and Roy Cullen Tower is set to open in 2026. Rendering courtesy of SLAM Architecture

Baylor College of Medicine has collected $100 million toward its $150 million fundraising goal for the college’s planned Lillie and Roy Cullen Tower.

The $100 million in gifts include:

  • A total of $30 million from The Cullen Foundation, The Cullen Trust for Health Care, and The Cullen Trust for Higher Education.
  • $12 million from the DeBakey Medical Foundation
  • $10 million from the Huffington Foundation
  • More than $45 million from members of Baylor’s Board of Trustees and other community donors, including the M.D. Anderson Foundation, the Albert and Margaret Alkek Foundation, and The Elkins Foundation.

“The Cullen Trust for Health Care is very honored to support this building along with The Cullen Foundation and The Cullen Trust for Higher Education,” Cullen Geiselman Muse, chair of The Cullen Trust for Health Care, says in a news release. “We cannot wait to see what new beginnings will come from inside the Lillie and Roy Cullen Tower.” Continue reading.

Cancer-fighting Houston lab led by Nobel laureate receives $5M grant at annual event

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

Allison, who won the Nobel Prize in 2018, leads his namesake institute that was founded in 2022 to advance translational and clinical within cancer to create new, synergetic therapies. In addition to his role as director of the institute, he is regental professor and chair of Immunology at MD Anderson. Continue reading.

The event spotlighted the organization’s strides in regenerative medicine, fueling advancements in adult stem cell therapies for conditions often deemed incurable, such as Parkinson’s Disease, multiple sclerosis, and spinal cord injuries. Photo via Si Vo

Houston gala attendees prescribe $1M for groundbreaking stem cell research

breaking boundaries

There’s a new gala in H-town, folks, and it made its grand, sold-out debut thanks to a power couple known for believing that the sky's the limit when it comes to local philanthropy. Chairs Jessica Rossman and Gordon Bethune piloted the inaugural Hope Biosciences Research Foundation (HBRF) fundraiser on October 26 at the Post Oak Hotel in Uptown Houston.

The event spotlighted the organization’s strides in regenerative medicine, fueling advancements in adult stem cell therapies for conditions often deemed incurable, such as Parkinson’s Disease, multiple sclerosis, and spinal cord injuries.

The evening offered patrons a deeper look into the group’s pioneering work, led by co-founders Donna and Daniel Chang. More than 400 supporters — many of whom have witnessed the impact of HBRF’s clinical trials on their health and the lives of loved ones — were enticed to partake in the event by a host committee helmed by Donae, Bella, and Rob Chramosta.

Sherry Diers and David Gonzales, hosts of the foundation’s Hopeful News Network podcast, shared heartfelt stories from their hands-on experiences with HBRF patients. In a touching moment, high school senior Bella Chramosta recounted her own health journey before announcing the inaugural HBRF Luminary Award recipients — Ema Suljkanovic, Rachel Phillips, and Alayna Nunez. The three Kingwood High School students had raised $1,400 for the foundation, and Houston icon Jim “Mattress Mack” McIngvale proudly presented the award.

HBRF offered a Hope-inspired jewelry pull, sponsored by Thomas Markle Jewelers. Each silver necklace entry doubled as a ticket for a chance to win a diamond version of the necklace — 2.27 carats in 18kt white gold, valued at $7,500. The winning ticket, drawn by Sarah and Phillip Markle, brought cheers from those who purchased necklaces throughout the evening. Guests enjoyed a silent auction chaired by Cathy Jackson, featuring everything from health and beauty experiences to travel packages like golfing at St. Andrews and fishing in Cabo.

Gala-goers were treated to a meaningful musical performance by Faith and Jon Hartlage. Upon departure, each guest received a gift from Hope Biosciences, LLC — a tube of Wondercell gel, an anti-aging product made from stem cell byproducts, as a reminder of the foundation’s impact both inside and outside the lab.

Seen on the scene were Ginger and Dick Hite, Maria and Omar Alaoui, Roslyn Bazzelle Mitchell, Cheryl Byington, Gracie and Bob Cavnar, Anna Dean, Karen and Peter Remington, Dr. Romy Dell’Ario, Jan Duncan, Nene Foxhall, Mandy Kao, Stacey Lindseth, Linda McIngvale, Beth Muecke, Patti Murphy, Jennifer Pinkerton, Rachel and Tom Regan, Dallas Rowdan, Ally Shell, Natalie Wall, Christina Zhou, Tama Lundquist and Dr. Peter Farrell, Stephanie and Gary Loveless, Azeemeh Zaheer, Chris Perry, Gregg Harrison, and Dr. Roland Maldonado.

------

This article originally ran on CultureMap.

The university is not disclosing the amount of the donation. Photo via Rice University

Rice's undergraduate business school receives a 'historic' donation

cha-ching

Following a “generous philanthropic gift” by Farid and Asha Virani, the undergraduate business program at Rice University will be named after the family. The building where the business program is housed, McNair Hall, will remain unchanged.

“We are profoundly grateful to Farid and Asha Virani for their extraordinary gift, which will transform our undergraduate business education,” Rice president Reginald DesRoches said in a statement. “Their success and commitment to excellence inspire our students, and their generosity will serve as a lasting testament to what can be accomplished through vision and determination.”

Rice University declined to disclose the size of donation that has led to the creation of the Virani Undergraduate School of Business on the request of the Virani family to maintain privacy, saying only that the amount is historic. The business school currently serves roughly 300 undergrads.

Dr. Asha Virani is a proud Rice alumna who graduated in 1989. Her husband, Farid, is the founder and CEO of Prime Communications, a wildly successful AT&T retailer that started with a single store in Baybrook Mall and has grown to be the largest such retailer in the nation. Their son, Faraz, graduated from Rice in 2021 after studying sports management.

“We are incredibly excited to support Rice Business, as we believe in the transformative power of education. This contribution will play a pivotal role in preparing the next generation of business leaders and entrepreneurs to tackle the challenges and seize the future opportunities — not just for our city, but for our state and our country,” Farid Virani said.

“Our vision is to foster a culture of curious and compassionate lifelong learners who will lead with a strong ethical orientation and intellectual humility,” Asha Virani said.

A new associate dean position will be created to oversee the new business school, and a national talent search is underway to fill the job. The gift will help expand the current business undergraduate offerings, including new major focuses in areas like healthcare and artificial intelligence.

Rice launched its undergraduate business program in 2021. Last year, the university announced its plans to expand its business school, a project that is currently underway.

------

This article originally ran on CultureMap.

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. Photo via TMC.edu

Energy co. makes $100,000 donation to Houston hospital

curing ALS

Where do energy transition and life-saving medicine meet? In Texas, of course.

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. The grant is part of a $200,000 gift that has spanned the past two years. The goal? To eradicate the neurological disorder, ALS (amyotrophic lateral sclerosis). There is currently no cure for ALS. For roughly 90 percent of patients, there’s no known genetic cause, meaning the disease can strike anyone.

Houston Methodist currently has numerous clinical trials taking place with the goal to slow or halt the progression of the degenerative ailment.

“Every dollar donated to ALS research is a beacon of hope for those battling the disease,” said Chris Curia, executive vice president and chief human resources officer at Energy Transfer. “Those affected by ALS deserve a chance at a better life. We are hopeful this donation brings us one step closer to a world without this disease.”

Houston Methodist is home to the first multidisciplinary care clinic for ALS patients in the region and is actively engaged in both clinical and basic scientific research to support people battling ALS.

“We appreciate Energy Transfer’s generosity in our efforts to improve the quality of life and to provide hope for ALS patients and their families. Their continued commitment to Houston Methodist’s ongoing ALS research is truly transformational,” says Stanley H. Appel, M.D., a pioneering neurologist at Houston Methodist whose lab focuses on neurodegenerative diseases, including ALS.

Energy Transfer’s gift will help to support one particularly promising trial of a combination therapy that is currently moving into Phase 2. In its first phase, the therapy was found to safely slow disease progression in four ALS patients over a six-month period. Those patients had no significant progression of their disease during the trial. Prior to receiving the therapy, each of the patients had reported declining abilities to perform daily tasks.

Energy Transfer’s good deed could mean the world not only to patients at Houston Methodist, but to ending ALS altogether.

------

This article originally ran on EnergyCapital.

The Belfer family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium. Photo via mdanderson.org

$20M donation drives neurodegeneration research in Houston

big impact

Neurodegeneration is one of the cruelest ways to age, but one recent donation is invigorating research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

Here's what grant funding news stories trended this year on InnovationMap. Photo via Pexels

Money moves: Most-read Houston innovation grant and gift news of 2023

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. Money means a lot to startups and other innovative entities, and while startups are usually scouting venture capital investors, grants and donations are key too. These are the most-read news articles about grants and gifts — be sure to click through to read the full story.

Houston-based battery innovators receive $4M in federal funding

Houston-based Zeta Energy has fresh funding from the government. Image via Zeta Energy

Houston-based Zeta Energy announced this week that it was selected to receive $4 million in federal funding for the development of efficient electric vehicle batteries.

The funds come from the U.S. Department of Energy's ARPA-E Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program, which aims to increase the number of EVs on the roads by boosting the country’s supply chain of affordable, convenient, reliable and safe batteries.

Zeta Energy is one of 12 groups in the U.S. to receive funding from the program, which awarded $42 million in total.

“Electric vehicle sales in America have tripled since the start of this Administration and by addressing battery efficiency, resiliency and affordability, the projects announced today will make EVs attractive to even more drivers,” U.S. Secretary of Energy Jennifer M. Granholm said in a statement released earlier this week. “This is a win-win for our efforts to fight climate change and power America’s clean transportation future with technologies produced by researchers and scientists right here at home.”

Continue reading the article from January.

Fresh off grant, Houston health tech company's AI aims to revolutionize diagnostics, care

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Continue reading the article from January.

Houston organization announces nearly $28M in Texas research grant funding

The Welch Foundation, a Houston-based nonprofit, has doled out fresh funding to research organizations, with over a third being deployed to Houston-area institutions. Photo via Getty Images

Five schools in the Houston area have landed $10.8 million in research grants from the Houston-based Welch Foundation.

The 36 grants were awarded to Rice University, Texas A&M University, the University of Houston, the Baylor College of Medicine, and the University of Texas Medical Branch in Galveston.

In all, the foundation announced nearly $28 million in Texas research grants for 2023. All of the money — in the form of 91 grants for 15 Texas colleges and universities — goes toward chemical research. This year’s total for grant funding matches last year’s total.

“The Welch Foundation continues to emphasize the creative pursuit of basic chemical research,” Adam Kuspa, the foundation’s president and a former dean at the Baylor College of Medicine, says in a news release. “Our funding allows investigators throughout the state to follow their curiosity and explore the foundations chemical processes.”

Continue reading the article from July.

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Continue reading the article from July.

Massive $32M gift from former patient, new UH deal pump big changes into Houston organization

The Texas Heart Institute recently received its largest charitable donation in its history. Photo courtesy of THI

Leadership at The Texas Heart Institute has two major things to celebrate. First, it just received a $32 million donation from a patient — the largest charitable donation in its history.

Shortly after that news came out, the institute announced a new partnership with the University of Houston Tilman J. Fertitta Family College of Medicine that allows those UH medical students to join a clinical rotation at The Texas Heart Institute. The alliance means valuable insights and experience with both inpatient and outpatient cardiology for UH's future doctors.

"Students will have the chance to develop their skills in the diagnosis and management of cardiovascular conditions and will be taught by outstanding clinical educators,” said Dr. Joseph G. Rogers, president and CEO of The Texas Heart Institute and heart failure specialist at The Texas Heart Institute Center for Cardiovascular Care, in a press release announcing the news.

Continue reading the article from August.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.